No Data
Perspective Therapeutics Is Maintained at Outperform by RBC Capital
BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $6
B of A Securities Downgrades Perspective Therapeutics to Neutral, Lowers Price Target to $6
RBC Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Cuts Target Price to $16
RBC Cuts Price Target on Perspective Therapeutics to $16 From $25, Keeps Outperform, Speculative Risk
Cautious Hold Rating for Perspective Therapeutics Amid Efficacy and Safety Concerns
No Data
No Data
